Whitbread urges rejection of board nominee from 6.4% shareholder Corvex
Key Facts
Whitbread's board urged shareholders to reject Corvex's bid for board representation, unanimously recommending a vote against the resolution at the general meeting scheduled for 9 November 2026. The resolution seeks to appoint James H. Gemmell to the board, according to the company's shareholder circular. Explaining its opposition, the board said that "adding another director with a completely different agenda would disrupt delivery of the plan", placing continuity in executing the company's strategy at the heart of its stance on the nomination. Corvex said in its response to the interim results that it owns about 6.4% of the company's ordinary shares. It added that its economic exposure to Whitbread is approximately 7%.
The board's defence of its plan coincided with half-year results showing group revenue rose 2% to £1572 million from £1541 million in the comparable period, according to Whitbread's announcement. Adjusted pretax profit, however, fell 9% to £287 million from £316 million in the previous first half. The decline in reported pretax profit was steeper, falling 62% to £109 million from £287 million. The company held its interim dividend unchanged at 36.4 pence per share, according to Investing's coverage of the results. In its report published on 13 October 2026, the website recorded a 3.2% rise in the shares to 2591 pence following the results, which it said beat market expectations.
On capital allocation, Chief Executive Dominic Paul said the company's review had reduced growth capital expenditure by £1 billion, according to the interim results. Whitbread also announced an agreement to sell 173 sites as part of its portfolio restructuring. Its plan targets an additional £275 million contribution to adjusted pretax profit from key growth initiatives, according to the business review's findings. The review's targets also include increasing the group's return on capital employed by 500 basis points. The company aims to make £2 billion of free cash flow available for shareholder returns by the financial year 2031.
Corvex had called on the board to conduct a comprehensive and rigorous sale process for Whitbread in a statement issued on 18 May 2026. Setting out the rationale for its campaign, it said total shareholder returns were approximately negative 17% over 10 years, according to Investing's coverage of the campaign in September 2026. It added that total returns were negative 18% over 5 years. Returns over the preceding year were negative 22%, according to figures Corvex presented in criticising the company's performance. Whitbread shares had previously risen more than 5% when Corvex disclosed a 6.05% stake and called for a strategic review, according to a report published by the website on 18 December 2025.
Responding to criticism over engagement, Whitbread said in its shareholder circular that management, the investor relations team and the chairman had met with Corvex on 18 occasions between February 2025 and July 2026. The company said it had engaged Goldman Sachs, J.P. Morgan Cazenove and Morgan Stanley as advisers for its business and strategy review. Paul defended the plan, saying: "With excellent progress on strategic execution and strong current trading momentum, our plan is delivering," according to Investing's account of the chief executive's remarks. Corvex, meanwhile, said in its response to the results that it was "not calling for a sale of the company". That stance differs from its earlier demand for a comprehensive sale process, while it is now seeking a vote on Gemmell's appointment to the board.
According to Whitbread's circular, the general meeting to consider the resolution to appoint Gemmell will be held on 9 November 2026. The company set the meeting's start time at 1 p.m. London time. The deadline for receipt of proxy forms ahead of the vote is 5 November 2026. Those forms must be received by 1 p.m. London time, according to the notice to shareholders. The proposed resolution provides for the nominee's appointment to take effect immediately if approved by shareholders.